Varicella-Zoster Virus Antibody (Immunity Screen), ACIF
Test Code
14505
86787
Clinical Significance
Varicella-Zoster Virus Antibody (Immunity Screen), ACIF - A positive titer (≥1:4) by anticomplement immunofluorescence (ACIF) indicates a history of past infection by Varicella-Zoster virus infection or vaccination. This antibody is usually detectable within 2 days after the onset of rash and is, thereafter, detectable for life. Conversely, the absence of detectable antibody can be used as evidence of susceptibility to varicella (chickenpox).
Test Resources
Test Details
Methodology
Anti-Complement Immunofluorescence (ACIF)
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Reference Range(s)
| <1:4 | Antibody Not Detected |
| Evidence for susceptibility to VZV infection | |
| ≥1:4 | Antibody Detected |
| Evidence for immunity against VZV infection | |
Preferred Specimen(s)
1 mL serum
Minimum Volume
0.075 mL
Transport Container
Transport tube
Transport Temperature
Room temperature
Specimen Stability
- Room temperature: 7 days
- Refrigerated: 14 days
- Frozen: 30 days
Setup Schedule
1 mL serum
0.075 mL
Transport tube
Room temperature
Room temperature: 7 days
Refrigerated: 14 days
Frozen: 30 days
Refrigerated: 14 days
Frozen: 30 days